Treatments used to prevent and treat male pattern baldness, the difficulty in finding a permanent cure for hair loss, and the potential financial motivations of companies not wanting to find a cure.
Hair loss theories discussed include poor blood flow, scalp tension, inflammation, and DHT. Treatments mentioned are massaging scalp, minoxidil, finasteride, and RU58841.
AltruisticBro's experience with Fluridil (Eucapil) as a hair loss treatment, and the current blood work results associated with it. They are not willing to take finasteride due to potential permanent side effects.
Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.
OP is experiencing significant hair loss despite GFC and PRP treatments and has abnormal lab results. They are advised to consult a hair-focused dermatologist for further evaluation.
Breezula's potential as a hair loss treatment is debated, with some seeing promise despite delays, while others suggest alternatives like Pyrilutamide. Breezula is compared to topical finasteride, with hopes for a better side effect profile.
The user is considering using P5P to reduce high prolactin levels and is questioning if oral minoxidil could be contributing to the issue. They are also debating whether to switch from oral to topical minoxidil.
Essential oils like rosemary, thyme, lavender, and cedar wood in a carrier oil may effectively treat alopecia areata and potentially male pattern baldness by stimulating the scalp similarly to minoxidil. The user plans to try this routine and share results.
Hair loss can begin in early adolescence and cause mental anguish. Treatments mentioned include eating cruciferous vegetables, engaging in physical activity, and maintaining scalp hygiene.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.
The user reduced their finasteride dosage from 1.25mg to 1mg and experienced scalp burning and itching. They are concerned about potential hair loss and are seeking advice from others who have made similar dosage changes.
The user is experiencing a burning sensation on their scalp despite using finasteride and nizoral for hair loss, and is unsure if they should switch to dutasteride. They have reduced their testosterone dose but the burning persists, and a trichologist suggested it might be telogen effluvium.
The user is experiencing severe hair shedding despite using minoxidil, finasteride, ketoconazole shampoo, and dermarolling. They are considering changing treatments after stopping dermarolling and switching finasteride brands worsened the shedding.
The conversation is about the mental toll of hair loss and seeking alternatives to finasteride. Suggestions include using minoxidil, considering pumpkin seed oil, and possibly seeking counseling for body dysmorphic disorder.
The conversation is about the effectiveness and trustworthiness of Pyrilutamide hair loss treatment sold by Hairlisciously, with concerns about product purity and a request for alternative suppliers. No specific treatments were confirmed to be used by participants.
The user experienced hair thinning with dandruff and itchiness but not complete baldness, and found relief using dermarolling and castor oil. They did not use minoxidil or finasteride and discussed the potential impact of lifestyle choices on hair loss.
Finasteride, dutasteride, and minoxidil are discussed as effective hair loss treatments, with mixed opinions on their use and side effects. The conversation highlights a divide between supporting medical treatments and accepting baldness.
The conversation is about choosing a topical antiandrogen for hair loss, with options including RU58841, CB0301, Pyrolutamide, Alfatradiol, and Fluridil. Users discuss their preferences and reasons for selecting specific treatments.
Finasteride can cause pelvic or urethral discomfort for some users. Reducing the dose to 0.25 mg on Mondays, Wednesdays, and Fridays is being considered as a potential solution.
Switching from liquid to foam Minoxidil to avoid scalp irritation, with a method to melt the foam for easier application. Users discuss alternatives and personal experiences with Minoxidil, including issues with propylene glycol and different application methods.
The user experienced hair loss since 2019 and tried finasteride, dutasteride, RU58841, and ketoconazole shampoo without success. A scalp biopsy showed scarring and inflammation from folliculitis, indicating chronic inflammation was affecting treatment effectiveness.
A user is concerned about hair loss and acne from a one-week course of 70 mg/day oral prednisolone for severe tinnitus. They are asking if these side effects are common.
Sunburns on the scalp can cause permanent hair loss, especially for those using Tretinoin or Tacrolimus. Wearing UPF 50+ hats is recommended to protect against UV radiation.
User has itching, dandruff, and scalp issues, considering Nizoral 1% shampoo for treatment. Nizoral's effectiveness for hair loss is uncertain due to limited research, short contact time, and concentration differences.
The user experienced excessive scalp oiliness and high testosterone levels after switching from finasteride to dutasteride. They plan to manage their condition with finasteride and are considering spironolactone to reduce testosterone and restore dry skin.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.